James Carmichael

21k citations
69 papers · 18.2k · 9 hit papers · h-index 35

Impact in

  • Oncology top 0.2%
    • PARP inhibition in cancer therapy
    • Lung Cancer Research Studies
    • Drug Transport and Resistance Mechanisms
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • PARP inhibition in cancer therapy 10
    • Drug Transport and Resistance Mechanisms 6
    • Cancer Treatment and Pharmacology 5
    • Breast Cancer Treatment Studies 7

James Carmichael

68 papers receiving 17.4k citations

James Carmichael's Hit Papers

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer 2012 · 1.6k citations
1.6k0+13+26Years since publication1k2k3k

Peers

James Carmichael
Comparison fields: 5 of 132
  • Oncology 7.6k
  • Cancer Research 2k
  • Reproductive Medicine 1.3k
  • Genetics 2k
  • Molecular Biology 3.1k
Replace Timothy Anthony Yap with:
Timothy Anthony Yap United States
Scott H. Kaufmann United States
Ross C. Donehower United States
Bryan T. Hennessy Ireland
Maurizio D’Incalci Italy
Stan B. Kaye United Kingdom
Ernest T. Hawk United States
Yasuhiro Fujiwara Japan
Wilson H. Miller Canada
James L. Abbruzzese United States
James Carmichael relative to Timothy Anthony Yap United States Timothy Anthony Yap's profile →
Citations per field
00.5×1.6×
Timothy Anthony Yap · 1×
Citations per year

Countries citing papers authored by James Carmichael

Since Specialization
Citations

This map shows the geographic impact of James Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Carmichael more than expected).

Fields of papers citing papers by James Carmichael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Carmichael. The network helps show where James Carmichael may publish in the future.

Co-authors

The 25 scholars most cited alongside James Carmichael, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James Carmichael Line = papers co-authored together James Carmichael links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
Hit paper breakdown →
19873563
2
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Hit paper breakdown →
20093069
3
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Hit paper breakdown →
20101955
4
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Hit paper breakdown →
20121554
5
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Hit paper breakdown →
20101453
6
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Hit paper breakdown →
2011966
7
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Hit paper breakdown →
2010854
8
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
Hit paper breakdown →
1999787
9
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity.
Hit paper breakdown →
1987635
10 2011408
11 2008294
12 2002226
13
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
2002186
14 2008182
15 2013170
16 2011142
17 1989130
18 2004123
19 199297
20 201380

About James Carmichael

James Carmichael is a scholar working on Oncology, Cancer Research, Pharmacology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 69 papers that have together received 18.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (10 papers), Breast Cancer Treatment Studies (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Effects of Radiation Exposure (6 papers), Nausea and vomiting management (5 papers), Glutathione Transferases and Polymorphisms (5 papers), Cancer Treatment and Pharmacology (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). The work is most often cited by research in Oncology (7.6k citations), Cancer Research (2k citations), Reproductive Medicine (1.3k citations), Genetics (2k citations) and Molecular Biology (3.1k citations). James Carmichael has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include William DeGraff, Adi F. Gazdar, John Dorrance Minna, Andrew N.J. Tutt, Michael Leonard Friedlander, Stan B. Kaye, Ursula A. Matulonis, Timothy Anthony Yap, Jan H.M. Schellens and Mark Wickens. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer Chemotherapy and Pharmacology, The Lancet and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact